The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Hepatitis B Virus (HBV) peptides. Buy the report here.
Smarter leaders trust GlobalData
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
See Also:
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Hepatitis B Virus (HBV) peptides is a key innovation area in pharmaceutical
HBV peptides represent peptides derived from the hepatitis B virus (HBV). These may serve as HLA class I-restricted T cell epitopes and can be used as an antigen-specific positive control to stimulate T cells. Vaccination with these peptides is a promising new treatment strategy for chronic HBV.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 50+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of Hepatitis B Virus (HBV) peptides.
Key players in Hepatitis B Virus (HBV) peptides – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to Hepatitis B Virus (HBV) peptides
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| Compagnie Merieux Alliance | 62 | Unlock Company Profile |
| Globeimmune | 58 | Unlock Company Profile |
| GSK | 52 | Unlock Company Profile |
| Kuros Biosciences | 50 | Unlock Company Profile |
| TheVax Genetics Vaccine | 49 | Unlock Company Profile |
| Melbourne Health | 32 | Unlock Company Profile |
| Yangshengtang | 24 | Unlock Company Profile |
| Advanced Biological Laboratories | 24 | Unlock Company Profile |
| Worg Pharmaceuticals Hangzhou | 21 | Unlock Company Profile |
| Green Cross Holdings | 21 | Unlock Company Profile |
| Biomay | 21 | Unlock Company Profile |
| Fastilium Property Group | 21 | Unlock Company Profile |
| F. Hoffmann-La Roche | 19 | Unlock Company Profile |
| iQur | 18 | Unlock Company Profile |
| Xiamen Innovax Biotech | 17 | Unlock Company Profile |
| Austin Health | 17 | Unlock Company Profile |
| Valneva | 17 | Unlock Company Profile |
| Academia Sinica | 16 | Unlock Company Profile |
| Westinghouse Air Brake Technologies | 16 | Unlock Company Profile |
| International Centre for Genetic Engineering and Biotechnology | 15 | Unlock Company Profile |
| Bharat Biotech | 15 | Unlock Company Profile |
| Gilead Sciences | 15 | Unlock Company Profile |
| Biomed Realty Trust | 13 | Unlock Company Profile |
| Southern Health | 13 | Unlock Company Profile |
| Biogen | 12 | Unlock Company Profile |
| PowderJect Vaccines | 12 | Unlock Company Profile |
| Johnson & Johnson | 11 | Unlock Company Profile |
| Altimmune | 11 | Unlock Company Profile |
| Cue Biopharma | 11 | Unlock Company Profile |
| HU Group Holdings | 11 | Unlock Company Profile |
| Dynavax Technologies | 11 | Unlock Company Profile |
| Precigen | 10 | Unlock Company Profile |
| Chimeros | 10 | Unlock Company Profile |
| Siemens | 10 | Unlock Company Profile |
| Proteome Sciences | 10 | Unlock Company Profile |
| Shanghai HEP Pharmaceutical | 9 | Unlock Company Profile |
| Endo International | 9 | Unlock Company Profile |
| St Vincent’s Health Australia | 9 | Unlock Company Profile |
| Gulftech International | 9 | Unlock Company Profile |
| ISA Pharmaceuticals | 8 | Unlock Company Profile |
| Lion TCR | 8 | Unlock Company Profile |
| Hualan Biological Engineering | 8 | Unlock Company Profile |
| Sanofi | 8 | Unlock Company Profile |
| German Cancer Research Center | 8 | Unlock Company Profile |
| Celltrion | 7 | Unlock Company Profile |
| Alfred Health Victoria | 7 | Unlock Company Profile |
| Japan Science and Technology Agency | 7 | Unlock Company Profile |
| SJ Biomed | 7 | Unlock Company Profile |
| Beacle | 6 | Unlock Company Profile |
| Catalent | 6 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Globeimmune is the leading patent filer in Hepatitis B Virus (HBV) peptides. It is focused on the treatment of cancer and infectious diseases based on proprietary Tarmogen platform. Tarmogens activate a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominately stimulate antibody production.
In terms of application diversity, Proteome Sciences is the top company, followed by Biogen and Chimeros. By means of geographic reach, Celltrion holds the top position, while Biomay and Catalent stand in the second and third positions, respectively. To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
